UK regulator urges caution over misuse of obesity injections

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning to healthcare professionals, urging vigilance for signs of misuse involving popular obesity injections like Wegovy. The advisory follows reports of individuals using these weight-loss drugs without medical need, leading to severe health complications.

The MHRA emphasised that these injectable medications are specifically designed for patients living with obesity or type 2 diabetes. Health Secretary Wes Streeting endorsed the regulator’s caution, stressing the importance of responsible use. “These are serious medicines, not cosmetic drugs for an Instagram-ready body, they should be used only under medical supervision and not as a quick fix for shedding a few pounds.”

Though the majority of side effects from these drugs are mild — such as nausea, bloating, and diarrhoea — MHRA officials note that some cases can result in significant health issues. Dr. Alison Cave, MHRA Chief Safety Officer, reminded doctors of the risks: “We encourage healthcare professionals to ensure patients are aware of common side effects and how to mitigate them.”

Medical experts are reporting troubling incidents of misuse. Dr. Vicky Price, President of the Society for Acute Medicine, shared with the BBC that she has seen non-overweight patients admitted with gastrointestinal problems after taking these injections. “Diarrhoea, vomiting, constipation, and severe dehydration are common issues,” she said.

Despite the concerns, weight-loss drugs can be highly effective when used correctly. Streeting reiterated that, alongside diet and exercise, these medications have the potential to transform health outcomes for people with obesity. However, the MHRA warns that only patients fitting the approved indications for weight management or diabetes should receive these treatments, and buying them online without a proper medical assessment poses significant health risks.